8-K: InMed Pharmaceuticals Announces Positive Preclinical Data for INM-089 in Dry AMD Treatment

InMed Pharmaceuticals has released additional preclinical data showing positive effects of INM-089 in treating dry Age-Related Macular Degeneration (AMD).

Summary

• InMed Pharmaceuticals announced new preclinical data for INM-089, a drug targeting dry Age-Related Macular Degeneration (AMD).
• The data demonstrates significant functional and pathological improvements in an AMD model.
• INM-089 is a small molecule compound that acts as a preferential signaling ligand for CB1 and CB2 receptors.
• Preclinical studies showed neuroprotection of photoreceptors, improved photoreceptor function, improved retinal pigment epithelium integrity, and a reduction in extracellular autofluorescent deposits.
• The company believes INM-089 could slow the progression of dry AMD and fill a significant treatment gap.
• Dry AMD accounts for 85-90% of all AMD cases and is a leading cause of blindness.
• Geographic Atrophy (GA), an advanced form of dry AMD, affects approximately 5 million people globally, with projections of 18.5 million cases by 2040.
• InMed is working with a Contract Development and Manufacturing Organization (CDMO) to scale up manufacturing of the active pharmaceutical ingredient (API).
• Internal development of the drug product formulation is also ongoing.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data for a drug targeting a significant unmet medical need, which is a strong positive signal for investors. The company is also actively working on scaling up manufacturing and drug formulation, indicating progress in development.

Positives

• INM-089 showed positive results in preclinical studies for dry AMD.
• The drug has the potential to slow the progression of dry AMD.
• INM-089 targets a significant unmet need in the treatment of dry AMD.
• The company is actively working on scaling up manufacturing and drug formulation.

Risks

• The efficacy of INM-089 is still under investigation and may not be as effective as hoped.
• The marketability and uses for INM-089 are not yet fully established.
• The development of INM-089 is subject to various risks and uncertainties.
• The company's actual results may differ materially from forward-looking statements.

Future Outlook

InMed plans to continue preclinical activities to further understand the mechanism of action of INM-089, including receptor interactions and drug metabolism and pharmacokinetics (DMPK) studies. They are also working on scale-up manufacturing and drug product formulation to support further development.

Management Comments

• Dr. Eric Hsu, SVP of Preclinical Research and Development, stated, 'We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model.'
• Dr. Eric Hsu also stated, 'We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease.'

Industry Context

This announcement is relevant to the pharmaceutical industry's focus on developing new treatments for age-related macular degeneration, a significant cause of vision loss. The development of a drug targeting both CB1 and CB2 receptors is a novel approach in this space.

Comparison to Industry Standards

• Current treatments for dry AMD have limited efficacy and can have undesirable side effects, creating a need for new therapies.
• Companies like Apellis Pharmaceuticals with their drug Syfovre, and Iveric Bio with Izervay, are also targeting geographic atrophy, but INM-089's mechanism of action is different, focusing on CB1 and CB2 receptors.
• The preclinical results of INM-089 showing improvements in retinal pigment epithelium integrity, neuroprotection, and photoreceptor function are promising compared to the current standard of care.

Stakeholder Impact

• Shareholders may view this news positively due to the potential for a new treatment for dry AMD.
• Patients with dry AMD may benefit from the development of INM-089.
• Employees of InMed may be motivated by the progress of the company's drug development program.

Next Steps

• InMed will continue scale-up manufacturing process development of the active pharmaceutical ingredient (API).
• The company will continue internal development work on drug product formulation.
• Additional preclinical activities are ongoing to further understand the mechanism of action, including receptor interactions and drug metabolism and pharmacokinetics (DMPK) studies.

Key Dates

Keywords

INM-089, Dry Age-Related Macular Degeneration, AMD, Geographic Atrophy, CB1 receptor, CB2 receptor, Cannabinoid, Preclinical Data, Retinal Pigment Epithelium, Photoreceptors, Neuroprotection